Pamedic Spotlight｜Forging a "Golden Age" for China's Nuclear Pharmaceutical Sector

China's nuclear medicine market size keeps growing, according to industry forecasts. In the next few years, China’s nuclear medicine size is expected to reach 26 billion yuan by 2030, an annual growth rate of 17% in five years. "Golden Age" of China’s nuclear medicine marke definitely will unfold under such a bouncy momentum.

1. [Full Life Technologies Closes US$63.3 Million Financing to Help Advance the Radiopharmaceutical Therapeutic Pipeline and UniRDC™ Platform]

Shanghai/Jeanblu/Heidelberg, January 4, 2024 - Full Life Technologies Company Limited ("Full Life Technologies"), a fully integrated, international radiopharmaceutical therapeutics company, announced that it has closed a US$63.3 million financing round, of which US$47.3 million in Series B equity financing and an additional US$16 million in credit facilities. The financing was jointly led by Prosperity7 Ventures, a subsidiary of Aramco Ventures, and a specialized investment fund in the life sciences sector, and also attracted follow-on investments from investors such as Sky9 Capital, Amazing Healthcare US Dollar Fund, Amazing Grace Fund, and Guanghua Wutong Fund. The funds will be used to accelerate the development of its radiopharmaceutical pipeline, expand its manufacturing capacity and further optimise its proprietary discovery platform, UniRDC™.

(Source:Full-Life official website)

(Source:Full-Life official website)

2. [Eilink Bio and Roche enter into a global collaboration to advance the development of YL211, a next-generation oncology therapeutic medicine]

On January 2, 2024, Medilink Therapeutics entered into a global collaboration and license agreement with Roche. The parties will jointly develop YL211, a next-generation antibody-drug conjugate candidate, primarily for the treatment of solid tumors. Roche is paying an initial payment of US$50 million and milestone payments up to or including US$1 billion, as well as royalties based on net sales.YL211 is based on the technology of Medilink Therapeutics TMALIN® ADC platform and uniquely targets mesenchymal epidermal transforming factor (c-MET). The medicine has demonstrated potential in multiple preclinical trials and is currently in the clinical filing stage. This collaboration marks an innovation in the field of oncology therapeutics by Medilink Therapeutics, aiming at providing more effective treatment options for oncology patients around the world.This major collaboration brings a certain amount of attention to the pharmaceutical field and demonstrates the strategic partnership between Medilink Therapeutics and Roche, which will work together to advance the development of next-generation antibody-drug conjugate and innovations for the treatment of solid tumors.

3. [Bristol Myers Squibb (BMS) Acquires RayzeBio for $4.1 Billion to Build Strength in Radiopharmaceutical Therapeutics]

December 26, 2023 - Bristol Myers Squibb (NYSE: BMY) (BMS) will acquire radiopharmaceutical therapeutics company RayzeBio, Inc. (NASDAQ: RYZB) for $62.50 per share in cash, with a total equity value of approximately $4.1 billion and estimated net cash from the acquisition of $3.6 billion.

(Britol Myers Squibb official website)

It is understood that nearly 70 innovative medicine license out deals occurred in the country in 2023, with a total disclosed deal value of more than $35 billion. China's innovative medicine License Out deals have reached a new high and become the focus of the global innovative medicine market.

As an R&D company in the field of isotopic nuclear medicine, Pamedic Holdings understands the importance of the industry development, and will seizes the development opportunities in the market and strengthens cooperation with international peers. Pamedic Holdings believes that by deepening international cooperation, we can promote the sharing and exchange of nuclear medicine technology on a global scale.

About Pamedic:

  Pamedic Holdings has always been committed to realizing innovative breakthroughs in the field of nuclear medicine. We will closely monitor the industry trends, and in order to strengthen our competitiveness and meet the diversified needs of patients, Pamedic Holdings (Pamedic) plans to continue to increase its investment in research and development (R&D), to expand its product lines and to strengthen its technological innovations. By combining the introduction of cutting-edge international technologies with our own R&D, we are committed to bringing China's nuclear medicine industry to the international stage and providing patients with more advanced and personalized treatment options.